The potential of bisphosphonate risedronate edible film strips to inhibit post-orthodontic tooth relapse (literature review)

Drugs called bisphosphonates are used to treat metabolic abnormalities brought on by several types of cancer, including osteoporosis, bone disease and pain. Numerous studies have been conducted utilizing different kinds of bisphosphonates to promote anchoring and prevent tooth relapse in orthodontic treatment. Nevertheless, using bisphosphonates clinically can result in jaw osteonecrosis, which depends on the dose, duration, and dosage form applied. Hence, applying bisphosphonates as edible film strips (efs) is anticipated to prevent the negative effects. This literature review aims to explore the potential of bisphosphonate risedronate in the dosage form of efs to prevent tooth relapse. Efs is an alternative dosage form to help those with difficulties taking medications in bigger dosage forms. This form has drawn interest since, in contrast to synthetic preparations, it is non-toxic and can biodegrade naturally. Efs will be absorbed directly and enter the systemic circulation without going through hepatic first-pass metabolism and increases bioavailability, which will reduce the dose required to achieve the desired pharmacological effect, thereby reducing side effects and toxicity. In the oral cavity, this system works by dissolving the drug in the salivary fluid of the oral mucosa in a short time, thus providing a rapid release of the active ingredient. Patients after orthodontic treatment have the good dental condition and no longer require invasive procedures, such as tooth extraction which can trigger side effects of osteonecrosis of the jaw. Using bisphosphonate risedronate as edible film strips can potentially prevent relapse after orthodontic tooth movement and avoid side effects.